Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN Trials.
Muhammad Atif ZahoorJoshua B FeldHsing-Hua Sylvia LinAlexander I MosaLoghman SalimzadehRobert P PerrilloRaymond T ChungKathleen B SchwarzHarry L A JanssenAdam J GehringJordan J FeldPublished in: Hepatology (Baltimore, Md.) (2024)
The development of anti-IFNα nAbs during PegIFNα treatment diminishes responses to antiviral therapy. Understanding how and why anti-IFNα antibodies develop may allow for the optimization of IFN-based therapy, which is critical given its renewed use in HBV-cure strategies.